Overview
Nemera Szczecin designs and manufactures drug delivery devices and provides services for drug-device combination products. It serves the pharmaceutical, biotechnology and generic drug industries, supporting the development of safe, high-quality treatments.
Financials
Revenue history (in m)
Filing timeliness
5 of 6 financial statements were filed late (the longest delay 95 days for 2021). All were audited by a statutory auditor.
- 202515/09/2026
- 202419/08/2025
- 202323/09/2024
- 202219/07/2023
- 202118/10/2022
- 202015/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
CPhI Worldwide Milan 2026
Join us at Booth 11A25 in the Packaging & Drug Delivery zone and meet our team. We look forward to seeing you there.
SCHOTT Pharma and Nemera launch first fully compatible large-volume passive safety system with prefillable glass syringe
Seamless compatibility between SCHOTT Pharma’s syriQ BioPure® 5.5 ml prefillable glass syringe and Nemera’s Safe’n’Sound® passive safety system
Nemera expands production capacity in Ponts-et-Marais, France
Nemera today inaugurated a new production facility in Ponts-et-Marais, France. Hall 3 will expand the production capacity of Nemera’s Ponts-et-Marais.
Nemera launches DuoSpray, strengthening its systemic intranasal delivery platform portfolio
Nemera announces the launch of DuoSpray in September 2026, a bidose nasal spray platform designed to support nasal drug-device combination product development for systemic drug administration.
Industry
Offer
- Drug delivery devices
- Spray pumps
- Airless packaging
- Analytical testing services
- Device design verification
- Regulatory consulting services
Website technology
- Website
- WordPress
- Analytics and marketing
- Google Analytics
- Google Tag Manager
Authorized Representatives
Manner of representation
Each member of the management board independently is authorised to submit declarations, sign documents and perform legal acts on behalf of the company; however, with respect to disposing of a right or incurring an obligation to provide a performance with a value exceeding PLN 5,000.00, two members of the management board acting jointly are authorised. If the management board consists of only one person, that person is authorised to independently submit declarations, sign documents and perform legal acts on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Financière N Sas | 280,210 | $37,845,759.05 | 99.9376% |
| 175 | $23,635.87 | 0.0624% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2005-06-01.
68 1240 3927 1111 0010 9474 9198- 32 1240 3927 1111 0011 3264 4254
- 80 1240 3927 1978 0011 1748 5500
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Land (incl. perpetual usufruct) | $5.8M$5,783,566 |
Buildings and premises | $26.8M$26,803,427 |
Public aid
37 public aid cases recorded, with a total value of $2,934,730.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 26, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Enea S.A. | |
| Aug 13, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Jul 31, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Prezes Banku Gospodarstwa Krajowego |
European Funds
5 projects co-financed from European Funds recorded, with total EU co-financing of $3,143,466.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-09-01 | Obtaining international patent protection for the invention „Mechanizm sterujący aplikatora i sposób jego montażu” | $33,101$33,101 | Operational Programme Smart Growth | |
| 2019-01-01 | Obtaining international patent protection for the invention “Urządzenie do monitorowania stanu aplikatora wstrzykującego substancję farmaceutyczną oraz sposób monitorowania stanu aplikatora za pomocą tego urządzenia” | $24,077$24,077 | Operational Programme Smart Growth | |
| 2018-07-01 | Research and development work on developing an innovative reusable injector with therapy monitoring and wireless connectivity | $2M$1,954,164 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Waste generation | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Meden - Inmedsp. z o.o. | $76,366,389.05 | meden.com.pl | ||
| InmedS.A. | $13,860,648.96 | inmed.pl | ||
| SMSsp. z o.o. | $9,534,586.27 | sms.com.pl | ||
| Extrudansp. z o.o. | $8,241,066.38 | extrudan.com | ||
| Infimedsp. z o.o. | $5,587,133.78 | infimed.pl | ||
| CM InternationalS.A. | $4,905,625.86 | cos-medico.eu |
Change history
| Date | Event | |
|---|---|---|
| 2025-08-13 | Share capital increase (80,192,500.00 PLN → 140,192,500.00 PLN) | |
| 2024-07-19 | Share capital increase (80,192,000.00 PLN → 80,192,500.00 PLN) | |
| 2024-07-11 | Share capital increase (87,500.00 PLN → 80,192,000.00 PLN) | |
| 2023-04-05 | Address change (Litewska 10 A, 71-344, Szczecin → Ul. Tytanowa 3, 70-856, Szczecin) | |
| 2021-10-26 | PKD change (Removed: 26.60.Z) |
FAQ
Last updated: 2026-09-15